ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Participants With Myelofibrosis

ClinicalTrials.gov ID: NCT03222609

Public ClinicalTrials.gov record NCT03222609. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label Study Evaluating Tolerability and Efficacy of Navitoclax Alone or in Combination With Ruxolitinib in Subjects With Myelofibrosis (REFINE)

Study identification

NCT ID
NCT03222609
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
191 participants

Conditions and interventions

Interventions

  • Navitoclax Drug
  • Ruxolitinib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2017
Primary completion
Mar 27, 2022
Completion
Jan 28, 2025
Last update posted
Jan 19, 2026

2017 – 2025

United States locations

U.S. sites
33
U.S. states
19
U.S. cities
30
Facility City State ZIP Site status
UAB Comprehensive Cancer Cente /ID# 165464 Birmingham Alabama 35217
TOI Clinical Research /ID# 222546 Cerritos California 90703-2679
City of Hope /ID# 221395 Duarte California 91010
Moores Cancer Center at UC San Diego /ID# 164084 La Jolla California 92093
Long Beach Memorial Medical Ct /ID# 230148 Long Beach California 90806-1701
University of Southern California /ID# 164095 Los Angeles California 90033
Colorado Blood Cancer Institute /ID# 224250 Denver Colorado 80218
Baptist MD Anderson Cancer Center - Jacksonville /ID# 222548 Jacksonville Florida 32207-8432
Mayo Clinic /ID# 164201 Jacksonville Florida 32224
Moffitt Cancer Center /ID# 164082 Tampa Florida 33612-9416
University of Chicago Medicine /ID# 164115 Chicago Illinois 60637-1426
Mid Illinois Hematology & Oncology Associates, Ltd /ID# 230536 Normal Illinois 61761
Indiana Blood & Marrow Transpl /ID# 165075 Indianapolis Indiana 46237
Duplicate_American Oncology Partners of Maryland, PA /ID# 231299 Bethesda Maryland 20817
Dana-Farber Cancer Institute /ID# 162675 Boston Massachusetts 02215
University of Massachusetts - Worcester /ID# 222547 Worcester Massachusetts 01655
Henry Ford Hospital /ID# 162682 Detroit Michigan 48202
Ascension Providence Southfield Cancer Center /ID# 223876 Southfield Michigan 48075-3707
MidAmerica Division, Inc. /ID# 222058 Kansas City Missouri 64132
Weill Cornell Medical College /ID# 162679 New York New York 10065
The Ohio State University /ID# 217402 Columbus Ohio 43210-1280
Bend Memorial Clinic /ID# 224184 Bend Oregon 97701
West Penn Hospital /ID# 222618 Pittsburgh Pennsylvania 15224-1722
Duplicate_Medical University of South Carolina /ID# 222597 Charleston South Carolina 29425
Prairie Lakes Healthcare System /ID# 224358 Watertown South Dakota 57201
Tennessee Oncology-Nashville Centennial /ID# 221410 Nashville Tennessee 37203-1632
Texas Oncology - West Texas /ID# 224784 Abilene Texas 79606
Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 225159 Dallas Texas 75246-2003
Oncology Consultants /ID# 230930 Houston Texas 77030-3306
MD Anderson Cancer Center at Texas Medical Center /ID# 162683 Houston Texas 77030-4000
University of Texas Health San Antonio MD Anderson Cancer Center /ID# 164094 San Antonio Texas 78229
Utah Cancer Specialists Salt Lake Clinic /ID# 222806 Salt Lake City Utah 84106
University of Utah /ID# 164116 Salt Lake City Utah 84112-5500

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 58 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03222609, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2026 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03222609 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →